News

BioLineRx Announces FDA Approval of Aphexda for Multiple Myeloma Treatment

1 Mins read

BioLineRx, a leading biopharmaceutical company, has received FDA approval for the use of Aphexda motixafortide in combination with filgrastim to mobilize stem cells for the treatment of patients with multiple myeloma.

What is Aphexda?

Aphexda is a groundbreaking medication that effectively mobilizes hematopoietic stem cells from the peripheral blood. These stem cells can then be collected and used for autologous transplantation, which has shown great promise in the treatment of multiple myeloma.

The Importance of Stem Cell Mobilization

Successful autologous stem cell transplantation requires adequate mobilization of stem cells during the treatment process. Aphexda has demonstrated its ability to effectively mobilize these vital cells, improving the outcomes for patients with multiple myeloma.

FDA Approval Based on Promising Results

The FDA’s approval of Aphexda was based on the compelling results of a comprehensive Phase 3 trial. This trial evaluated the safety and efficacy of Aphexda in combination with filgrastim, compared to a placebo with filgrastim.

Multiple Myeloma: A Persistent Challenge

Multiple myeloma is an aggressive and currently incurable blood cancer that primarily affects certain white blood cells. It is the second most common hematologic malignancy, posing significant challenges to healthcare providers and patients alike.

With the FDA approval of Aphexda, BioLineRx is set to make this innovative treatment available to patients later this month.

Related posts
News

IMF commends Sri Lanka's new govt for reform continuation

1 Mins read
COLOMBO, Apr 25: The International Monetary Fund (IMF) on Friday commended the Sri Lankan government, led by President Anura Kumara Dissanayake, for…
News

U.S. Federal Reserve revokes crypto guidance for banks

1 Mins read
25th April 2025 – (Washington) The U.S. Federal Reserve announced on 24th April that it will withdraw previous guidance requiring state member…
News

Largo Reports Q1 2025 Production and Sales Results; Provides Update on Operational Turnaround Plans By Investing.com

7 Mins read
All dollar amounts expressed are in thousands of U.S. dollars unless otherwise indicated.Trending NowBest Forex Trading Robots To Invest In 2022 Q1…

Leave a Reply

Your email address will not be published. Required fields are marked *

− 1 = 7